Alzheimer's - Dementia, Author Interviews, Herpes Viruses / 08.01.2025

MedicalResearch.com Interview with: [caption id="attachment_65850" align="alignleft" width="150"]Dr. Or Shemesh PhDThe Harvey M. Krueger Family Center for Center for Nanoscience and Nanotechnology School of Pharmacy - Institute for Drug Research The Hebrew University of Jerusalem Dr. Or Shemesh[/caption] Dr. Or Shemesh PhD The Harvey M. Krueger Family Center for Center for Nanoscience and Nanotechnology School of Pharmacy - Institute for Drug Research The Hebrew University of Jerusalem MedicalResearch.com: What is the background for this study? Response: Our study investigated the connection between herpes simplex virus 1 (HSV-1) and Alzheimer's disease (AD) pathologies. We explored how HSV-1 proteins are present in the brains of individuals with AD and examined their interactions with tau, a key protein in AD pathology. MedicalResearch.com: What are the main findings? Response:  The main finding is that tau, traditionally seen as detrimental, might initially act as a protective response to HSV-1 by reducing neuronal death through an antiviral innate immunity pathway called cGAS-STING . Over time, this (initially beneficial) antiviral response of tau can manifest as the well established tau toxicity in Alzheimer's disease.
Author Interviews, Herpes Viruses, JAMA, STD, USPSTF / 23.02.2023

MedicalResearch.com Interview with: [caption id="attachment_59720" align="alignleft" width="133"]James Stevermer, M.D., M.S.P.H. Vice chair for clinical affairs Professor of family and community medicine University of Missouri Medical director of MU Health Care Family Medicine–Callaway Physicians Dr. Stevermer[/caption] James Stevermer, M.D., M.S.P.H. Vice chair for clinical affairs Professor of family and community medicine University of Missouri Medical director of MU Health Care Family Medicine–Callaway Physicians, Dr. Stevermer joined the U.S. Preventive Service Task Force in January 2021.     MedicalResearch.com: What is the background for this study? Response: Genital herpes is a common sexually transmitted infection (STI) that unfortunately has no cure and cannot accurately be detected in people who do not have signs of the condition. The current screening tests have limitations and there is a high chance that test results will say a person has the condition when they do not. In addition, the available treatments are focused on managing symptoms and preventing the condition from reoccurring. As a result, the Task Force concluded that the harms of screening outweigh the benefits.
Author Interviews, Diabetes, Genetic Research, Herpes Viruses / 12.05.2022

MedicalResearch.com Interview with: [caption id="attachment_59137" align="alignleft" width="150"]Prof. Annette Peters PhD Chair of Epidemiology Institute of Medical Information Sciences, Biometry and Epidemiology, Ludwig-Maximilians University Munich, Germany Institute of Epidemiology, Helmholtz Zentrum München, German Research Centre for Environmental Health, Neuherberg, Germany German Center for Diabetes Research (DZD), München-Neuherberg, Germany Prof. Peters[/caption] Prof. Annette Peters PhD Chair of Epidemiology Institute of Medical Information Sciences, Biometry and Epidemiology, Ludwig-Maximilians University Munich, Germany Institute of Epidemiology, Helmholtz Zentrum München, German Research Centre for Environmental Health, Neuherberg, Germany German Center for Diabetes Research (DZD), München-Neuherberg, Germany MedicalResearch.com:  What is the background for this study?  What are the main findings? Response: A large number of genetic, behavioural and environmental risk factors have been identified as contributing to the risk of type 2 diabetes. However, little is known about a potential link between virus infections and type 2 diabetes developments. We had the unique opportunity to use a multiplex assay to measure antibodies for herpes viruses by the Waterboer laboratory at the German Cancer Center in Heidelberg and set out to investigate the potential associations in the prospective KORA cohort. First of all, we detected that herpes virus antibodies were highly prevalent in the study population at baseline and increased with age. We found an association between Herpes simplex virus 2 and cytomegalovirus and type 2 diabetes during a seven year follow-up. These associations were robust against controlling for other known risk factors.
Author Interviews, Herpes Viruses, Science, University of Pennsylvania, Vaccine Studies / 23.09.2019

MedicalResearch.com Interview with: [caption id="attachment_51550" align="alignleft" width="148"]Harvey M. Friedman, MD Professor of Medicine/Infectious Diseases University of Pennsylvania Philadelphia, PA 19104-6073  Prof. Friedman[/caption] Harvey M. Friedman, MD Professor of Medicine/Infectious Diseases University of Pennsylvania Philadelphia, PA 19104-6073  MedicalResearch.com: What is the background for this study? Response:  Mice and guinea pigs are the animal models used to evaluate candidate vaccines for preventing genital herpes. My lab has been working on such a vaccine. Our candidate vaccine contains 3 immunogens. One immunogen is a protein on the virus that is required for the virus to enter cells (viruses need to enter cells to replicate). The other two immunogens are proteins on the virus that help the virus escape immune attack. Our intent is to produce antibodies to these 3 proteins by immunization and that the antibodies will bind to the proteins on the virus and block the protein functions. The virus then will not be able to enter cells and will not be able to use its evasion strategies to avoid the immune responses generated by the vaccine. Our vaccine aimed at preventing immune evasion is novel as a component of a genital herpes vaccine. 
Author Interviews, Herpes Viruses / 15.08.2019

MedicalResearch.com Interview with: Tejabhiram Yadavalli, Ph.D Department of Ophthalmology and Visual Sciences Chicago, IL MedicalResearch.com: What is the background for this study? What are the main findings?  Response: Charcoal black is a common ingredient used in the cosmetic industry, especially for the eye in products such as eyeliners. Traditionally, black soot obtained from burning clarified butter was used as an eyeliner and is still used today in various cultures across the world. Activated charcoal is highly porous in nature and has a surface area far greater than any other nanoparticle or microparticle known to materials science. Since our lab works on ocular herpes infection we wanted to see whether activated charcoal can influence viral infection potentially by trapping the virus particles and rendering them ineffective. As hypothesized, we found excellent restriction of the virus from infecting the host. The most interesting results came when we applied charcoal in tandem with existing clinical antiviral (Acyclovir). This is where we saw that charcoal can absorb the drug on its surface and slowly release it over a period of time conferring protection for an extended period of time from viral infection. These antiviral drugs have to be taken multiple times a day to show comprehensive protection against the virus. However, we found that the drugs mixed with charcoal were need to be given with much reduced frequency to show excellent antiviral activity. This charcoal platform termed as DECON was effective in controlling both ocular and genital herpes infections.
Author Interviews / 17.10.2018

MedicalResearch.com Interview with: "Herpes" by LEONARDO DASILVA is licensed under CC BY 2.0Prof Ruth Itzhaki PhD Emeritus Professor Division of Neuroscience & Experimental Psychology The University of Manchester MedicalResearch.com: What is the background for this study? What are the main findings?  Response: Over 30 million people worldwide suffer from Alzheimer’s disease and unfortunately, this figure will rise as longevity increases, so the need for effective treatments is extremely urgent. Current treatments, at best, alleviate symptoms but do not prevent further deterioration. Our research has strongly implicated a common virus in the development of the disease, indicating a direct route to treatment: very effective and safe antiviral agents are available to combat the virus and thus to treat AD patients. They indicate also the future possibility of preventing the disease by vaccination against the virus in infancy. The virus implicated in Alzheimer's disease, herpes simplex virus type 1 (HSV1), is the one that causes cold sores. It infects most humans in infancy and thereafter remains lifelong in the body in latent (i.e., dormant) form within the peripheral nervous system (PNS - the part other than the brain and the spinal cord). Occasionally, if the person is stressed, the virus becomes activated and in some people it then causes cold sores. 
Author Interviews, BMJ, Dermatology, Herpes Viruses, HIV, Infections, STD / 12.12.2016

MedicalResearch.com Interview with: [caption id="attachment_30448" align="alignleft" width="165"]E. Charles Osterberg, M.D. Assistant Professor of Surgery Genitourinary Reconstruction and Trauma University of Texas- Dell Medical School Dell-Seton Medical Center / University Hospital Dr. Osterberg[/caption] E. Charles Osterberg, M.D. Assistant Professor of Surgery Genitourinary Reconstruction and Trauma University of Texas- Dell Medical School Dell-Seton Medical Center / University Hospital MedicalResearch.com: What is the background for this study? Response: Pubic hair grooming has become an increasingly common practice among men and women. Perceptions of genital normalcy have changed as modern society’s definition of attractiveness and feelings of femininity and masculinity have changed. Pubic hair grooming has been shown to increase morbidity such as genital injuries, however little is known about the relationship between grooming practices and sexually transmitted infections.
Author Interviews, Herpes Viruses, Vaccine Studies / 28.03.2016

MedicalResearch.com Interview with: [caption id="attachment_22946" align="alignleft" width="200"]Zeena Y. Nawas, MD Clinical Research Fellow Center for Clinical Studies Houston, TX, 77004 Dr. Zeena Nawas[/caption] Zeena Y. Nawas, MD Clinical Research Fellow Center for Clinical Studies Houston, TX, 77004 MedicalResearch.com: What is the background for this study? What are the main findings? Dr. Nawas: T cell immunity is believed to be particularly critical to the control of genital herpes, an incurable, lifelong sexually transmitted disease that affects roughly 500 million people worldwide. Genital herpes is characterized by recurrent, painful genital lesions and can be transmitted to sexual partners, even when there is no visible sign of the infection. Current genital herpes therapies only partially control the infection in some patients. These individuals continue to experience clinical symptoms and viral shedding, which drives disease transmission. Incomplete control of genital lesions and transmission risk, and the inconvenience of taking a daily medication are hurdles for effective long-term disease management. GEN-003, is a first-in-class immunotherapy developed by Genocea Biosciences and is intended to treat genital herpes by inducing both a T cell and B cell (antibody) immune response. GEN-003 has demonstrated promising results to date by showing statistically significant reductions in the clinical signs of genital herpes and viral shedding, as well as safety and tolerability in its Phase 1/2 and Phase 2 clinical studies.
Author Interviews, Herpes Viruses, Ophthalmology, Vaccine Studies / 30.01.2016

[caption id="attachment_21150" align="alignleft" width="125"]Frederick W. Fraunfelder, MD MBA Chairman and Roy E. Mason and Elizabeth Patee Mason Distinguished ProfessorDepartment of Ophthalmology Missouri University School of Medicine Director of the Missouri University Health Care’s Mason Eye Institute Dr. Rick Fraunfelder[/caption] MedicalResearch.com Interview with: Frederick W. Fraunfelder, MD MBA Chairman and Roy E. Mason and Elizabeth Patee Mason Distinguished ProfessorDepartment of Ophthalmology Missouri University School of Medicine Director of the Missouri University Health Care’s Mason Eye Institute Medical Research: What is the background for this study? What are the main findings? Dr. Fraunfelder: The background starts with a paper by Hwang et al (Cornea. 2013 Apr;32(4):508-9.Reactivation of herpes zoster keratitis in an adult after varicella zoster vaccination. Hwang CW Jr1, Steigleman WA, Saucedo-Sanchez E, Tuli SS.) After reading this paper, I started keeping track of keratitis cases that were reported to my registry (www.eyedrugregistry.com) and also to the FDA and WHO spontaneous reporting databases. We found case reports in adults and children of keratitis occurring soon after vaccination, and we presented this at the American Academy of Ophthalmology’s annual meeting that we just held in Las Vegas in November 2015. The main findings are that in rare instances, relatively speaking, herpes infection can occur in the cornea of the eye within days to weeks after vaccination. This may especially be true in adults who have had shingles in the past which caused a keratitis in the past. This keratitis may reoccur after the vaccination, and primary care providers should inquire about this past medical/ocular history and advise of the risk of recurrent keratitis after the vaccination for shingles.
Author Interviews, Herpes Viruses, HIV, NEJM / 06.08.2015

Dr. Salim Abdool Karim at CAPRISA Doris Duke Medical Research Institute South AfricaMedicalResearch.com Interview with: Dr. Salim Abdool Karim at CAPRISA Doris Duke Medical Research Institute South Africa Medical Research: What is the background for this study? What are the main findings? Response: Globally, Herpes simplex virus type-2 (HSV-2) is among the most common sexually transmitted infections and is the leading cause of genital ulcers. Available global estimates indicate that approximately 417 million sexually active adults between the ages of 15 and 49 years had an existing prevalent HSV-2 infection in 2012. Current interventions to prevent HSV-2 infection, including condoms, circumcision, and antiviral treatment among heterosexual, HSV-2-discordant couples, have demonstrated protection levels ranging from 6% to 48%. This study showed that peri-coital tenofovir gel reduced HSV-2 acquisition in women by 51%, rising to 71% in high gel-users.
Author Interviews, Herpes Viruses, HIV, PLoS / 06.07.2014

MedicalResearch Interview with: Dr. Don C. Des Jarlais PhD Director, International Research Core, Center for Drug Use and HIV Research Research Fellow, NDRI Director of Research, Baron Edmond de Rothschild Chemical Dependency Institute, Beth Israel Medical Center Professor of Epidemiology, Department of Epidemiology and Population Health, Albert Einstein College of Medicine Medical Research: What are the main findings of the study? Dr. Des Jarlais: HIV infection among non-injecting users of heroin and cocaine doubled doubled over the last several decades, from 7% to 14%. Herpes simplex virus type 2 (HSV-2) increases both susceptibility to and transmissibility of HIV. We examined HSV-2 infection among non-injecting heroin and cocaine user over the same time period using stored serum samples. HSV-2 infection was strongly related to HIV infection, and both increased over time. We calculated population attributable risk percentages (PAR%) to estimate the extent to which HSV-2 was driving increased HIV infection. HSV-2 infection was responsible for approximately half of the increase in HIV infection
Annals Internal Medicine, Author Interviews, Herpes Viruses, HIV / 01.07.2014

Connie Celum, MD, MPH Professor of Global Health and Medicine Director, International Clinical Research Center University of Washington Harborview Medical Center Seattle WA 98104MedicalResearch.com: Interview with Connie Celum, MD, MPH Professor of Global Health and Medicine Director, International Clinical Research Center University of Washington Harborview Medical Center Seattle WA  98104 MedicalResearch: What are the main findings of the study? Dr. Celum: We conducted a randomized, double blind study of daily oral tenofovir and tenofovir combined with emtricitabine (FTC) as oral pre-exposure prophylaxis (PrEP) for HIV among HIV serodiscordant couples (in which onepartner had HIV and the other partner did not) in Kenya and Uganda. Because of recent studies showing that tenofovir gel could reduce the chances of becoming HSV-2 infected, we studied the subset of HIV-uninfected partners who did not have HSV-2 and compared the rates who became HSV-2 infected during follow-up among those  who received oral pre-exposure prophylaxis versus those who received placebo.  We found that oral pre-exposure prophylaxis reduced HSV-2 acquisition by 30%.
Thank you for visiting MedicalResearch.com Senior Editor, Marie Benz MD. For more information please email: info@MedicalResearch.com

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.